Business News • PR NewsWire • Nordic Nanovector: Promising Results From Preclinical Studies With a Novel CD37-targeted Alpha Therapy for B-cell Tumours Presented at TAT11

Nordic Nanovector: Promising Results From Preclinical Studies With a Novel CD37-targeted Alpha Therapy for B-cell Tumours Presented at TAT11

Nordic Nanovector: Promising Results From Preclinical Studies With a Novel CD37-targeted Alpha Therapy for B-cell Tumours Presented at TAT11

OSLO, Norway, April 2, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) notes that promising results from its preclinical research collaboration to develop a novel CD37-targeting alpha therapy for B-cell tumours have been reported today in an oral presentation at TAT11, the 11th...

View More : https://www.prnewswire.com:443/news-releases/nordic-nanovector-promising-results-from-preclinical-studies-with-a-novel-c...

Releted News by prnewswire

Moberg Pharma Gives Notice of Early Redemption of Bonds With ISIN SE0007953989

Greenlight Energy enters into $5,000,000 Credit Facility with V3 Commodities Group

BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance

Nordic Nanovector: Promising Results From Preclinical Studies With a Novel CD37-targeted Alpha Therapy for B-cell Tumours Presented at TAT11

Titan Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results

Volvo Group Capital Markets Day 2019